Why Adaptive Biotechnologies Shares Are Rising

Adaptive Biotechnologies Corp ADPT shares are trading higher by 12.58% to $7.25 after the company launched T-Detect Lyme, to help diagnose early lyme disease.

Adaptive Biotechnologies says, in a clinical validation study among patients with early Lyme disease, the T-cell test was more accurate than leading antibody tests. T-Detect Lyme has a specificity of ~99% and showed more than 1.5 times greater sensitivity than standard two-tiered testing.

See Also: We Asked 1,000 Readers Why They Chose To Buy Dogecoin Instead Of Bitcoin, Ethereum

Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.


According to data from Benzinga Pro, Adaptive Biotechnologies has a 52-week high of $43.40 and a 52-week low of $5.96.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Small CapMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!